ref_name,rx_name,iso_name,section,assay_name,potency_type,potency,cumulative_count,potency_upper_limit,potency_lower_limit,potency_unit,date_added
Monin21,BNT162b2_01,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,1936,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_02,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,656,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_03,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,671,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_04,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,518,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_05,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,507,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_06,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,430,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_07,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,356,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_08,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,748,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_09,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,11626,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_10,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,6792,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_11,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,2307,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_12,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,2286,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_13,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,873,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_14,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,764,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_15,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,161,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_16,hCoV-19/England/02/2020,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,708,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_01,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,697,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_02,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,122,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_03,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,50,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_04,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,217,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_05,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,80,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_06,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,220,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_07,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,132,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_08,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,208,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_09,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,7367,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_10,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,6776,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_11,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,385,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_12,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,514,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_13,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,98,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_14,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,276,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_15,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,125,1,NULL,1,NULL,2021-07-06
Monin21,BNT162b2_16,B.1.1.7 Spike,Figure 1C; Appendix Figure 3F,HIV pseudovirus,NT50,140,1,NULL,1,NULL,2021-07-06
